The significance of serum thyroglobulin measurement before and after the treatment of toxic nodular goiter with 131I
Conclusions The significant fall of thyroglobulin after RIT observed in patients in whom euthyroidism and hypothyroidism was achieved indicates that thyroglobulin values can be related to the treatment outcome. In patients with high initial thyroglobulin levels (above 400 ng/l), and possible unfavorable RIT outcome, higher radioiodine activities or other treatment options might be considered. Video abstract: http:/links.lww.com/NMC/A163 (Source: Nuclear Medicine Communications)
Source: Nuclear Medicine Communications - March 14, 2020 Category: Nuclear Medicine Tags: Original Articles Source Type: research
Long-term outcomes of radioiodine therapy for juvenile graves' disease with emphasis on subsequently detected thyroid nodules: a single institution experience from japan
Endocrine Practice, Ahead of Print. (Source: Endocrine Practice)
Source: Endocrine Practice - March 11, 2020 Category: Endocrinology Authors: Tetsuya Mizokami Katsuhiko Hamada Tetsushi Maruta Kiichiro Higashi Junichi Tajiri Source Type: research
[Development of a system for risk analysis in treatment with unsealed radioactive substances in nuclear medicine].
CONCLUSIONS: Nuclear medical therapies were assessed as very safe, the revealed risks are very low in respect to patient safety. FMEA method was a useful tool to identify processes with potential for optimization. The chosen procedure can be easily adopted in other nuclear medicine facilities considering structure specific aspects like technical and personal equipment and procedures. Then further risks might be detected or the here identified risk might be assessed differently. PMID: 32126578 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)
Source: Nuklearmedizin - March 3, 2020 Category: Radiology Authors: Kotzerke J, Fetzer P, Grosche-Schlee S, Hanel A, Freudenberg R, Brogsitter C Tags: Nuklearmedizin Source Type: research
Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer
The objective of this nationwide survey was to evaluate whether there has been a change in the practice regarding hospital release of differentiated thyroid cancer patients treated with 131I since the publication of Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 addressing patient release. Methods: A survey was emailed to approximately 25,000 members of ThyCa: Thyroid Cancer Survivors’ Association, Inc., and was available online from March to August 2018. Responses were included from adult patients regarding their most recent 131I therapy received between 2011 and 2018 ("after 2011"). Respon...
Source: Journal of Nuclear Medicine - March 2, 2020 Category: Nuclear Medicine Authors: Wu, D., Gomes Lima, C. J., Bloom, G., Burman, K. D., Wartofsky, L., Van Nostrand, D. Tags: Clinical Source Type: research
Long-term remission of steroid-resistant Graves' orbitopathy after administration of anti-thymocyte globulin - description of the first case.
CONCLUSIONS: Thymoglobulin may be useful in the management of severe steroid-resistant GO with dysthyroid optic neuropathy. The effectiveness of this new therapy requires a larger number of observations. PMID: 32096552 [PubMed - as supplied by publisher] (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - February 25, 2020 Category: Endocrinology Authors: Świerkot M, Kulawik G, Sarnat-Kucharczyk M, Jagoda K, Mrukwa-Kominek E, Chudek J Tags: Endokrynol Pol Source Type: research
Outcome of radioiodine therapy in thyroid cancer patients with recent contrasted computed tomography
Conclusion RIT in postthyroidectomy setting can be successfully performed within 90 days after CCT. Further research is needed to confirm our findings. (Source: Nuclear Medicine Communications)
Source: Nuclear Medicine Communications - February 19, 2020 Category: Nuclear Medicine Tags: Original Articles Source Type: research
Long-term outcome and prognostic factors of single-dose Radioiodine Therapy in patients with Graves' disease
Publication date: Available online 10 February 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Yi-Ting Yang, Jung-Fu Chen, Shih-Chen Tung, Ming-Chun Kuo, Shao-Wen Weng, Chen-Kai Chou, Feng-Chih Shen, Chih-Min Chang, Chia-Jen Tsai, Cheng-Feng Taso, Pei-Wen WangBackground/purposeFew studies exist investigating the effectiveness of radioiodine (RAI) therapy for hyperthyroidism patients in Asia. We herein investigated the real-world efficacy of single-dose RAI therapy in Taiwanese patients with Graves’ disease (GD).MethodsThis is a retrospective study of 243 patients with GD recorded between 1989 and 20...
Source: Journal of the Formosan Medical Association - February 11, 2020 Category: General Medicine Source Type: research
Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer
Thyroid, Ahead of Print. (Source: Thyroid)
Source: Thyroid - February 10, 2020 Category: Endocrinology Authors: Evert F.S. van Velsen W. Edward Visser Sjoerd A.A. van den Berg Boen L.R. Kam Tessa M. van Ginhoven Elske T. Massolt Robin P. Peeters Source Type: research
Long-term outcome and prognostic factors of single-dose Radioiodine Therapy in patients with Graves' disease.
Abstract BACKGROUND/PURPOSE: Few studies exist investigating the effectiveness of radioiodine (RAI) therapy for hyperthyroidism patients in Asia. We herein investigated the real-world efficacy of single-dose RAI therapy in Taiwanese patients with Graves' disease (GD). METHODS: This is a retrospective study of 243 patients with GD recorded between 1989 and 2016 in a tertiary referral hospital. Eu- or hypothyroid after RAI therapy were defined as the successful group. Kaplan-Meier curve and cox-regression model were used for analysis of prognostic factors. RESULTS: Of the 243 patients, 187 were females, wi...
Source: J Formos Med Assoc - February 10, 2020 Category: General Medicine Authors: Yang YT, Chen JF, Tung SC, Kuo MC, Weng SW, Chou CK, Shen FC, Chang CM, Tsai CJ, Taso CF, Wang PW Tags: J Formos Med Assoc Source Type: research
Investigation of post-therapeutic image-based thyroid dosimetry using quantitative SPECT/CT, iodine biokinetics, and the MIRD ’s voxel S values in Graves’ disease
Before radioiodine therapy for Graves ’ disease, the estimated thyroid-absorbed dose is calculated based on various clinical parameters. However, the actual accumulation of iodine in the thyroid during radioiod... (Source: EJNMMI Physics)
Source: EJNMMI Physics - January 28, 2020 Category: Radiology Authors: Naotoshi Fujita, Yumiko Koshiba, Shinji Abe and Katsuhiko Kato Tags: Original research Source Type: research
Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.
Authors: van Velsen EFS, Visser WE, van den Berg S, Kam BLR, van Ginhoven TM, Massolt ET, Peeters RP Abstract Background Although international guidelines have become more conservative on the use of radioactive iodine (RAI) therapy, it is still one of the cornerstones of the treatment of patients with advanced differentiated thyroid cancer (DTC). As a large proportion of females diagnosed with DTC is in their reproductive years, knowledge about the effect of RAI on their gonadal and reproductive function is important. Earlier studies evaluating Anti-Müllerian hormone (AMH) as a representative of ovarian reserv...
Source: Thyroid : official journal of the American Thyroid Association - January 15, 2020 Category: Endocrinology Tags: Thyroid Source Type: research
Analysis Natrium Iodide Symporter Expression in Breast Cancer Subtypes for Radioiodine Therapy Response
ConclusionNIS protein expression is detectable in breast cancer cells to varying degrees. HER2+ is the most likely to express NIS in the cell membrane followed by TN subtypes. This indicates that radioiodine could be used as a novel adjuvant treatment in breast cancer. (Source: Nuclear Medicine and Molecular Imaging)
Source: Nuclear Medicine and Molecular Imaging - January 3, 2020 Category: Nuclear Medicine Source Type: research
68Ga-DOTA-RGD2 PET/CT in radioiodine (131I) refractory thyroid cancer - Prospective comparison of diagnostic accuracy with 18F-FDG PET/CT and evaluation towards potential theranostics.
CONCLUSIONS: 68Ga-DOTA-RGD2 PET/CT showed a similar sensitivity to, but higher specificity and overall accuracy than 18F-FDG PET/CT in detection of lesions in RAIR-DTC patients. This novel application of the angiogenesis imaging modality can prove useful in RAIR-DTC, especially in patients with negative/ suspicious 18F-FDG PET/CT. Further, since majority of patients (82.1%) positive on 68Ga-DOTA-RGD2 PET/CT showed radiotracer avidity towards the higher end of the spectrum (grade IV and V), novel 177Lu-based theranostics can be a potential treatment for these patients. PMID: 31870227 [PubMed - as supplied by publisher] ...
Source: Thyroid : official journal of the American Thyroid Association - December 26, 2019 Category: Endocrinology Tags: Thyroid Source Type: research
Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer
AbstractObjectiveThe efficacy of low-dose radioiodine therapy (RIT) for intermediate-risk or high-risk differentiated thyroid cancer (DTC) patients is controversial. Because of the country's shortage of medical facilities for RIT, 1110-MBq RIT for higher risk DTC patients has been performed on an outpatient basis since 2010 in Japan. Herein, we addressed this issue and attempted to determine prognostic factors for the prediction of RIT outcomes.MethodsWe retrospectively analyzed the cases of 119 patients with papillary thyroid cancer who underwent their first RIT with 1110 MBq radioactive iodine (RAI) following a tot...
Source: Annals of Nuclear Medicine - December 13, 2019 Category: Nuclear Medicine Source Type: research
Predicting large-volume lymph node metastasis in the clinically node-negative papillary thyroid microcarcinoma: a retrospective study
This study aimed to determine clinical predictors for large-volume LNM in clinically node-negative PTMC. Methods A total of 947 clinically N0 PTMC patients who received total thyroidectomy with lymph node dissection and radioiodine therapy were included. Based on the LNM status, they were divided into two groups: large-volume LNM and small-volume LNM including those patients without LNM. The association between age, gender and other clinical factors and large-volume LNM were investigated. The recurrence-free survival was also compared among these groups. Results We found that male gender [odds ratio (OR) =&thi...
Source: Nuclear Medicine Communications - December 6, 2019 Category: Nuclear Medicine Tags: Original Articles Source Type: research
Ethanol Ablation of Neck Metastases from Differentiated Thyroid Carcinoma
Semin intervent Radiol 2019; 36: 381-385 DOI: 10.1055/s-0039-1696651Differentiated thyroid cancer often metastasizes to cervical lymph nodes, characteristically with slow growth rate and low-level aggressiveness. Cervical lymph node resection is the treatment of choice, but ethanol ablation offers a therapeutic option for patients with few nodes unresponsive to radioiodine therapy and who are poor surgical candidates. The ethanol ablation procedure is minimally invasive, guided sonographically, easily and safely repeated, and easily implemented with minimal technology and cost. Transient nerve injury is infrequent and virt...
Source: Seminars in Interventional Radiology - December 2, 2019 Category: Radiology Authors: Paz-Fumagalli, Ricardo Li, Xi Smallridge, Robert C. Tags: Review Article Source Type: research
The Transareola Endoscopic Approach Yields Adequate Oncological Dissection as Open Approach in the Treatment of Papillary Thyroid Carcinoma
Conclusions: Transareola endoscopic total thyroidectomy and central lymph nodes dissection are safe and effective. According to the evaluated postoperative specific factors, this technique achieves similar outcomes to open surgery in selected patients with PTC. (Source: Surgical Laparoscopy, Endoscopy and Percutaneous Techniques)
Source: Surgical Laparoscopy, Endoscopy and Percutaneous Techniques - December 1, 2019 Category: Surgery Tags: Original Articles Source Type: research
Can the basal serum thyroglobulin level be used to predict the recombinant human TSH-stimulated thyroglobulin level in differentiated patients with thyroid cancer?
This study investigated the correlation between basal thyroglobulin (Tg) and recombinant human thyroid-stimulating hormone (rhTSH)-stimulated Tg in differentiated patients with thyroid cancer, and sought to determine whether the basal Tg level predicts the rhTSH-stimulated Tg level. We retrospectively enrolled 177 patients with papillary thyroid cancer (mean age = 44 years; 50 males, 127 females) who received rhTSH before radioiodine therapy (RIT). Serum Tg levels were measured 7 days before the 1st rhTSH injection (basal Tg) and on the days of RIT (rhTSH-stimulated Tg). Patients were divided into 3 groups according to ...
Source: Medicine - December 1, 2019 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Differentiated thyroid carcinoma: a 5-years survival study at a referral hospital in Brazil
CONCLUSIONS: This cohort had a very high survival over a 5-year period. The prognosis was negatively influenced by age, distant metastasis and lymphadenectomy, whereas radioiodine therapy was found to be protective. (Source: Revista de Saude Publica)
Source: Revista de Saude Publica - November 29, 2019 Category: International Medicine & Public Health Source Type: research
Standardised quantitative radioiodine SPECT/CT imaging for multicentre dosimetry trials in molecular radiotherapy.
In conclusion, the dead-time and calibration factors varied between centres, with different models of system. However, global calibration factors may be applied to the same system model with the same crystal thickness, to simplify set-up of future multi-centre MRT studies. PMID: 31766032 [PubMed - as supplied by publisher] (Source: Physics in Medicine and Biology)
Source: Physics in Medicine and Biology - November 25, 2019 Category: Physics Authors: Gregory RA, Murray I, Gear J, Leek F, Chittenden SJ, Fenwick A, Wevrett J, Scuffham J, Tipping J, Murby B, Jeans S, Stuffins M, Michopoulou S, Guy M, Morgan D, Hallam A, Hall D, Polydor H, Brown C, Gillen G, Dickinson N, Brown S, Wadsley J, Flux G Tags: Phys Med Biol Source Type: research
Multimodal therapy of advanced differentiated thyroid cancer, with emphasis on the role of radioiodine
AbstractIntroductionDifferentiated thyroid cancer (DTC) accounts for 95% of all thyroid cancers and is generally an indolent tumor, tending to present with limited loco-regional disease with an excellent long-term survival after treatment. However, 5 –10% present with locally advanced disease and aero-digestive tract invasion or distant metastases that are the main cause of thyroid cancer-related deaths.MethodsThe present review aims to underline the complex management of advanced DTC including treatment of gross extra-thyroidal extension, recurrent loco-regional, or distant metastatic disease.ResultsRadioiodine ther...
Source: Clinical and Translational Imaging - November 22, 2019 Category: Radiology Source Type: research
Long-term outcome of rare oncocytic papillary (H ürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy
AbstractPurposeOncocytic (H ürthle cell) papillary thyroid carcinoma (OPTC) is a rare variant of the papillary thyroid carcinoma (PTC) which comprises approximately 1 to 11 % of PTC cases. Its clinical course and prognosis have not been comprehensively documented and the clinical outcome remains a controversial issue. Theref ore, we investigated the long-term prognosis after thyroidectomy and (adjuvant) initial radioactive iodine therapy (RIT) of OPTC compared to PTC.MethodsA total of 563 patients (47 with OPTC and 516 with PTC) with a median follow-up of 9.9 (0.3; 23.5) years were studied. All patients underwent...
Source: European Journal of Nuclear Medicine and Molecular Imaging - October 24, 2019 Category: Nuclear Medicine Source Type: research
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Authors: Li Z, Zhang Y, Wang R, Zou K, Zou L Abstract Thyroid cancer is the most common type of endocrine malignancy, and its incidence is increasing. Anaplastic thyroid cancer (ATC), referring to undifferentiated subtypes, is considered to be aggressive and associated with poor prognosis. Conventional therapies, including surgery, chemotherapy and radioiodine therapy, have been used for ATC, but these do not provide any significant reduction of the overall mortality rate. The tumorigenesis, development, dedifferentiation and metastasis of ATC are closely associated with the activation of various tyrosine cascades ...
Source: Experimental and Therapeutic Medicine - September 28, 2019 Category: General Medicine Tags: Exp Ther Med Source Type: research
Voice Outcome of Total Thyroidectomy in Comparison With Administration of Recombinant Human TSH
The larynx is an end-organ target for hormones, and thyroid hormone may act on the larynx. We objectively compared and analyzed the phonetic characteristics of patients who underwent total thyroidectomy before and after radioiodine therapy (RIT) according to administration of recombinant human TSH (rh-TSH). (Source: Journal of Voice)
Source: Journal of Voice - September 28, 2019 Category: ENT & OMF Authors: Yong Tae Hong, Seok Tae Lim, Ki Hwan Hong Source Type: research
Laser and radiofrequency ablations for benign and malignant thyroid tumors.
Authors: Mauri G, Gennaro N, Lee MK, Baek JH Abstract A growing body of evidence is being published regarding the safety and efficacy of minimally invasive image-guided ablation techniques. While clinical applications of these techniques are increasing, international societies have started to publish treatment guidelines and to make efforts to standardize both terminology and reporting criteria for image-guided thyroid ablations. Laser ablation and radiofrequency ablation (RFA) are among the most common ablation techniques either for benign and malignant thyroid nodules. Unlike laser ablation and RFA in the treatme...
Source: International Journal of Hyperthermia - September 22, 2019 Category: Internal Medicine Tags: Int J Hyperthermia Source Type: research
Genes, Vol. 10, Pages 709: Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
usso Livia Manzella Paolo Vigneri Thyroid cancer comprises different clinical and histological entities. Whereas differentiated (DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary (MTCs) tumors do not uptake radioactive iodine and display aggressive features associated with a poor prognosis. Moreover, in a majority of DTCs, disease evolution leads to the progressive loss of iodine sensitivity. Hence, iodine-refractory DTCs, along with ATCs and MTCs, require alternative treatments reflective of their different tumor biology. In the last decade, the molecular mechanisms promoting...
Source: Genes - September 13, 2019 Category: Genetics & Stem Cells Authors: Elena Tirr ò Federica Martorana Chiara Romano Silvia Rita Vitale Gianmarco Motta Sandra Di Gregorio Michele Massimino Maria Stella Pennisi Stefania Stella Adriana Puma Fiorenza Gian ì Marco Russo Livia Manzella Paolo Vigneri Tags: Review Source Type: research
Preliminary study on the efficacy of xerostomia treatment with sialocentesis targeting thyroid disease patients given radioiodine therapy
Radioiodine therapy has been widely used for thyroid disease patients, but hyposalivation and xerostomia may occur in 10~30% of patients. Sialocentesis is a procedure that removes inflammatory substances in th... (Source: Maxillofacial Plastic and Reconstructive Surgery)
Source: Maxillofacial Plastic and Reconstructive Surgery - September 5, 2019 Category: ENT & OMF Authors: Euy-Hyun Kim, Dong-Keon Lee, Chang-Woo Kim, In-Seok Song and Sang-Ho Jun Tags: Research Source Type: research
Radiosensitivity-related postirradiation hypothyroidism in Graves' disease patients.
CONCLUSIONS: The opposing changes in mRNA expression levels of Ku-70 in patients with hypothyroidism indicate its potential as a prognostic marker for hypothyroidism induced by 131I treatment. PMID: 31446546 [PubMed - as supplied by publisher] (Source: Hormones)
Source: Hormones - August 26, 2019 Category: Endocrinology Tags: Hormones (Athens) Source Type: research
Unfavorable responses to radioiodine therapy in n1b papillary thyroid cancer: a propensity score matching study
Endocrine Practice, Ahead of Print. (Source: Endocrine Practice)
Source: Endocrine Practice - August 14, 2019 Category: Endocrinology Authors: Yan-Qing Liu Hui Li Jie-Rui Liu Yan-Song Lin Source Type: research
Patients treated for hyperthyroidism are at increased risk of becoming obese: findings from a large prospective secondary care cohort.
Authors: Torlinska B, Nichols L, Mohammed MA, McCabe C, Boelaert K Abstract BACKGROUND: The most commonly reported symptom of hyperthyroidism is weight loss; successful treatment increases weight. Weight gain faced by patients with hyperthyroidism is widely considered as a simple re-accumulation of premorbid weight, whereas many patients feel there is a significant weight "overshoot" attributable to the treatment. We aimed to establish if weight gain seen following treatment for hyperthyroidism represents replenishment of premorbid weight or "overshoot" beyond expected regain and, if there is ex...
Source: Thyroid : official journal of the American Thyroid Association - August 4, 2019 Category: Endocrinology Tags: Thyroid Source Type: research
The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer.
This study was conducted to identify prognostic factors in patients with papillary thyroid cancer (PTC) at the time of first radioactive iodine (RAI) therapy, and to evaluate the clinical value of the thyroglobulin (Tg) increase after RAI. Methods: Serum Tg was sampled prior to (pre-Tg) and 7 days after RAI (post-Tg) in 680 patients with PTC. Patients were classified into excellent response (ER), biochemical incomplete response (BCIR), structural incomplete response (SIR), and indeterminate response (IR) groups using dynamic risk stratification at 6 to 18 months after RAI therapy. Results: After RAI therapy, 514 ...
Source: The Korean Journal of Internal Medicine - July 29, 2019 Category: Internal Medicine Authors: Kim HK, Yoon JH, Cho JS, Kwon SY, Yoo SW, Kang HC Tags: Korean J Intern Med Source Type: research
Physics aspects of setting up a multi-centre clinical trial involving internal dosimetry of radioiodine treatment of differentiated thyroid cancer.
Authors: Taprogge J, Leek F, Flux GD Abstract The field of molecular radiotherapy is expanding rapidly, with the advent of many new radiotherapeutics for the treatment of common as well as for rare cancers. Treatment outcome is dependent on the absorbed doses delivered to target volumes and to healthy organs-at-risk, which are shown to vary widely from fixed administrations of activity. There have been significant developments in quantitative imaging and internal dosimetry in recent years, although clinical implementation of these methods has been slow in comparison with external beam radiotherapy, partly due to th...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 19, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research
The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer.
Authors: Weber M, Binse I, Nagarajah J, Bockisch A, Herrmann K, Jentzen W Abstract Radioiodine therapy of thyroid cancer was the first successful radionuclide therapy in the treatments of cancer, although its clinical use is empirical and not based on precise dosimetry. 124I is a positron- emitting radionuclide and positron emission tomography/computed tomography (PET/CT) with 124I currently provides the most accurate estimation of the absorbed (radiation) dose to thyroid cancer lesions. In the application, serial 124I PET/CT scans are performed to determine the time uptake curves and to delineate the volumes of th...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 13, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research
The surgical dilemma of primary surgery for follicular thyroid neoplasms
Publication date: Available online 9 July 2019Source: Best Practice & Research Clinical Endocrinology & MetabolismAuthor(s): Julia I. Staubitz, Petra B. Musholt, Thomas J. MusholtAbstractFollicular thyroid carcinoma is the second most prevalent form of differentiated thyroid carcinoma, following papillary thyroid carcinoma. Preoperative diagnosis is hampered by the fact that fine-needle aspiration cytology as well as supplemental molecular analysis cannot unambiguously distinguish between follicular thyroid carcinoma and benign follicular thyroid adenoma. The 2017 WHO classification defines three histological subty...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - July 10, 2019 Category: Endocrinology Source Type: research
Radioiodine therapy of advanced DTC: clinical considerations and multidisciplinary approach.
Authors: Giovanella L, Scappaticcio L Abstract Differentiated thyroid cancer (DTC) accounts for 95% of all thyroid cancers and is generally an indolent tumor, treated effectively with surgery, radioactive iodine, and thyroid-stimulating hormone suppressive therapy. However, 5-10% of patients have advanced disease, with aerodigestive tract invasion, distant metastases, or radioiodine refractory disease, with poor prognosis. This review focuses on the approaches for treating advanced DTC, including management of gross extra-thyroidal extension, recurrent loco-regional or distant metastatic disease, the role of extern...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - July 6, 2019 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research
MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer
Conclusion: This study confirms the ability of MEK inhibition to induce iodine uptake in in vitro and in vivo models of ATC. The approach of using a MEK inhibitor before radioiodine treatment could readily be translated into clinical practice and provide a much-needed therapeutic option for patients with ATC. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - July 1, 2019 Category: Nuclear Medicine Authors: ElMokh, O., Taelman, V., Radojewski, P., Roelli, M. A., Stoss, A., Dumont, R. A., Dettmer, M. S., Phillips, W. A., Walter, M. A., Charles, R.-P. Tags: Basic Source Type: research
Cancers, Vol. 11, Pages 849: 10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis
Conclusions: In naTC patients who have pT3-4, pN+ disease or R1-2 resection, pEBRT improved LRF. Limited-field IMRT is preferred. (Source: Cancers)
Source: Cancers - June 19, 2019 Category: Cancer & Oncology Authors: St éphanie Servagi Vernat Jonathan Khalifa Xu-Shan Sun Emmanuel Kammerer Eivind Blais Jean-Christophe Faivre Terence Tai-Weng Sio Jianji Pan Hao Qiu Gil Bar-Sela Jean-Marc Simon Julia Salleron Juliette Thariat Tags: Article Source Type: research
Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments
ConclusionsSpontaneous serum TSH variations determine levothyroxine replacement therapy in athyreotic patients with DTC, requiring multiple dose changes. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - June 15, 2019 Category: Endocrinology Source Type: research
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial
Thyroid cancer is the most common endocrine malignancy. Some advanced disease is, or becomes, resistant to radioactive iodine therapy (refractory disease); this holds poor prognosis of 10% 10-year overall surv... (Source: BMC Cancer)
Source: BMC Cancer - June 14, 2019 Category: Cancer & Oncology Authors: Sarah R. Brown, Andrew Hall, Hannah L. Buckley, Louise Flanagan, David Gonzalez de Castro, Kate Farnell, Laura Moss, Rebecca Gregory, Kate Newbold, Yong Du, Glenn Flux and Jonathan Wadsley Tags: Study protocol Source Type: research
Potassium iodide therapy may not impair efficacy of radioiodine therapy for Graves hyperthyroidism if discontinued 2 weeks before administration of I-131
Conclusions: Pretreatment by KI does not impair therapeutic efficacy of RAI for GH if the drug is discontinued 2 weeks before administration of I-131 and is combined with low iodine diet for one week . Thus, pretreatment with KI may be feasible for patients with GH who are to undergo RAI. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - May 21, 2019 Category: Nuclear Medicine Authors: Tamura, M., Nakada, K., Kato, K., Kato, N., Mizukoshi, T., Masayuki, S. Tags: Thyroid and Para-Thyroid Source Type: research
Post total thyroidectomy elevated anti-thyroglobulin antibodies in patients with differentiated thyroid cancer - Residual disease or residual thyroiditis?
509Objectives: Elevated serum thyroglobulin (S.Tg) with negative anti-thyroglobulin antibody titre or a rising serum anti-thyroglobulin (S.ATg) titre is known to indicate biochemical disease in patients with differentiated thyroid cancer (DTC), post-surgery. However, histopathologic examination of the surgical specimen often shows foci of lymphocytic thyroiditis synchronous with the primary DTC. Whether this has implications on the serum titres of S. Tg and S. ATg merits further exploration. The present study was conducted to correlate baseline elevated S. ATg in patients of DTC with histopathology of total thyroidectomy s...
Source: Journal of Nuclear Medicine - May 21, 2019 Category: Nuclear Medicine Authors: Parihar, A., Lukose, T., Sood, A., Mittal, B., Bhattacharya, A. Tags: Thyroid and Para-Thyroid Source Type: research
Long-term outcome of Radioiodine Therapy in Brain Metastases from Differentiated Thyroid Cancer- Single Centre Cohort Study
Conclusions: We conclude, if brain metastases show avid radioiodine uptake, RAI therapy should be offered before EBRT or surgery. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - May 21, 2019 Category: Nuclear Medicine Authors: Bal, C., Ballal, S., Yadav, M. Tags: Therapy Concepts I: Endocrinology Source Type: research
Changes in thyroid stimulating hormone receptor antibody and thyroid weight following a single radioiodine therapy in hyperthyroidism over 9 years
Conclusions: After a single RAI, both TRAb and TW were significantly decreased compared with the pretreatment value during the 9-years follow up. Hypothyroidism was achieved in about 90% of the patients. Compared with TRAb, TW showed quicker decrease and reached about 9% of the pretreatment value. In contrast, TRAb remained positive 9years after RAI in more than 10% of the patients who attained euthyroidism or hypothyroidism. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - May 21, 2019 Category: Nuclear Medicine Authors: Nakada, K., Mizukoshi, T., Tamura, M., Kato, K., Kato, N., Masayuki, S. Tags: Endocrine (GCS) Posters Source Type: research
Comparison of two different types of treatment approaches using I131 for benign pathologies of the thyroid
Conclusions: We found comparable results concerning the success rates of the two treatment approaches. However prospective studies with a longer follow-up and large number of patients are necessary to confirm these results. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - May 21, 2019 Category: Nuclear Medicine Authors: Trabelsi, K., Ouedraogo, S., Ouattara, F., Tondeur, M., Garcia, C. Tags: Endocrine (GCS) Posters Source Type: research
Can we prolong radioiodine therapy interval for differentiated thyroid cancer patient with pulmonary metastases ?
Conclusions: For DTC patients with pulmonary metastases who needs repeated RAI, when serum Tg decreases and then keeps stable under TSH suppression after one RAI, prolonged time to the next RAI did not have significant impact on the efficacy of RAI, although the extent of Tg change becomes weak with RAI number increase. Moreover, prolonged RAI interval might reduce adverse events, and consequently benefit patients. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - May 21, 2019 Category: Nuclear Medicine Authors: Shi, L., Tian, R., Huang, R. Tags: Endocrinology (Clinical Therapy) Posters Source Type: research
Outcome of radioiodine therapy in risk stratified differentiated thyroid cancer
Conclusions: Radioiodine therapy has very good remnant ablation rates and good successful therapy rates in lymph nodal metastasis and moderate therapy success rates in lung metastasis and stabilization of the disease in skeletal metastasis.Risk stratification is well established to estimate recurrence/persistence of disease. Our study further reinforces that each patient should undergo initial risk stratification and dynamic risk stratification to improve outcome in thyroid cancer patients. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - May 21, 2019 Category: Nuclear Medicine Authors: Pradhan, P., Mammoottil, A., Gambhir, S., Mishra, S., Mishra, A. Tags: Endocrinology (Clinical Therapy) Posters Source Type: research
Role of serum thyroglobulin as a surrogate marker in evaluating outcome following radioiodine therapy in differentiated thyroid cancer
Conclusions: Serum level of thyroglobulin reflects the thyroid tissue burden in the body, hence can be used successfully to evaluate the disease burden at presentation, monitor the recurrences and progression of disease before and after radioioiodine therapy in differentiated thyroid cancer. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - May 21, 2019 Category: Nuclear Medicine Authors: Pradhan, P., Mammoottil, A., Gambhir, S., Mishra, S., Mishra, A. Tags: Endocrinology (Clinical Therapy) Posters Source Type: research